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1. Introduction 
Bilayer tablets are prepared with one layer of drug for 
immediate release while second layer designed to release drug, later, 
either as second dose or in an extended or conventional release manner. 
Bilayer tablet is suitable for sequential release of two drugs in 
combination and separate two incompatible substances. Each layer may 
contain a different medicinal agent with varying release profiles, and they 
are designed for many reasons such as to control the delivery rate of 
either single or two different active pharmaceutical ingredients and to 
separate incompatible active pharmaceutical ingredients from each 
other, to control the release of active pharmaceutical ingredients from 
one layer by utilizing the functional property of the other layer (such as, 
osmotic property) [1]. With the development of pharmaceutical research, 
dosage form of two or more active ingredients in combination have 
attracted much more interest because they can show synergistic 
cumulative effect and /or decreased side effects. But at the same time, 
there also exist some problems in the process of preparing such 
combinations solid dosage forms, such as incompatibility between the 
active ingredients or between active ingredients and excipients. The 
physical or chemical interaction between two or more drug components 
in same dosage form or between the active ingredient and 
pharmaceutically adjuvant can frequently occurs which results in toxic or 
no clinical effects [2]. 
Metoclopramide HCl (MTH) is an anti-emetic drug which was 
also effective in the treatment of nausea and pain associated with 
migraine while it also increases the gastric motility and reduces the 
gastric stasis problem associated with upper GI tract [3]. 
Aceclofenac (ACF) is a non-steroidal anti-inflammatory drug 
with a potent anti-inflammatory and analgesic activity than those of 
Diclofenac sodium and Indomethacin. The incidences of adverse GI 
reactions are very much less than the NSAID’s available in the market. 
The bioavailability of Aceclofenac is nearby 100%. It also has 99.97% 
protein binding property due to which the conventional dose of 
Aceclofenac may provide effect upto10-12 hrs. It has been also reported 
that NSAID’s are very useful in the treatment of migraine. According to 
report, Metoclopramide shows unacceptable degradation with the acidic 
environment when given together with NSAID’s [4]. 
The present work focuses on the immediate release dosage 
form of Metoclopramide HCl which gives faster onset of action by 
achieving peak plasma concentration readily, also reduce the gastric 
stasis problem which is very common during the migraine attacks and 
causes Aceclofenac to be readily available in the small intestine which is 
its main site of absorption. To prepare conventional tablet of Aceclofenac, 
this synergizes the effect of Metoclopramide HCl to prevent pain of 
migraine with the desired release pattern and to avoid the degradation of 
the drug. 
 
2. Materials and Methods 
2.1 Materials 
MTH was obtained as a gift sample from Ipca Laboratory 
(Mumbai, India). ASF was obtained as a gift sample from NuLife 
Pharmaceutical (Pune, India). PVP K30 was purchased from Sisco 
research Laboratories Pvt. Ltd (Mumbai, India). MCC, SSG and CCS were 
procured as a gift sample from Concept Pharmaceuticals Ltd. 
(Aurangabad, India). Magnesium Stearate, Lactose, Pre-gelatinized starch 
were purchased from S.D. Fine Chemical Ltd. (Mumbai, India). All others 
reagents and chemicals used were of analytical reagent grade.  
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2.2 Methods  
2.2.1 Preparation of Conventional Release Layer of ACF 
Weighed quantity of drug ACF, micro crystalline cellulose MCC, 
PVP K-30 and lactose were mixed uniformly with the help of mortar and 
pastel. A solution of alcohol and water (1:1) was prepared this water 
alcohol solution was added to drug excipient mixture to form a damp 
mass. This damp mass was forced manually to pass through the sieve no 
16. Granules were obtained these granules were dried at 60°C for 4hrs. 
Dried granules were passed through 18 # sieve.  Granules were collected 
and to this 10% of the fines were added. The resulting granules were 
mixed with lubricant Magnesium stearate and colloidal silicon dioxide in 
a polyethylene bag for 5 min. The granules equivalent to 100 mg were 
compressed using a multi-station tablet compression machine (Rimek 
MINI, India) using 8 mm die. Composition of all batches was represented 
in Table 1. 
 
Table 1: Composition of ACF conventional Layer 
 
Formulation A1 A2 A3 A4 A5 A6 A7 A8 
ASF 66 66 66 66 66 66 66 66 
MCC 8 10 12 14 8 10 12 14 
PVP K-30 5 6 7 8 9 10 11 12 
Cab-o-sil 2 2 2 2 2 2 2 2 
Magnesium 
Stearate 
2 2 2 2 2 2 2 2 
Lactose 17 14 11 8 13 10 7 4 
Total 100 100 100 100 100 100 100 100 
*Each values represented in mg 
* ASF: Aceclofenac, MCC: Microcrystalline cellulose, PVP: Polyvinyl 
pyrolidone 
 
2.2.2 Preparation of Immediate Release Tablets of MTH 
MTH immediate release can be prepared by wet granulation as 
well as direct compression. But here intermediate addition technique 
was chosen for the addition of the superdisintegrants because of better 
results of it than intragranular (addition during preparation of dough 
mass) and extragranular (addition after preparation of granules) 
technique[5].  
  The formulations were subjected to optimization techniques to 
identify the minimum quantity of super disintegrant required to get the 
desired release profile. In Design of Experiments approach, process 
variables are first ‘screened’ to determine which are important to the 
outcome (excipient type, percentage, disintegration time (DT), etc.). Next 
step is the ‘optimization’, when the best settings for the important 
variables are determined. It involves the use of ‘mixture designs’ for 
changing mixture composition and exploring how such changes will 
affect the properties of the mixture. 
The aim of the current study was to develop and optimize the 
fast disintegrating tablets of MTH with low friability and minimum DT, 
prepared by wet granulation technique for oral delivery. A computer 
aided optimization process using a simplex centroid mixture design was 
employed to investigate the effect of three independent variable (factors) 
i.e.; amount of superdisintegrants: SSG, CCS and PGS. The DT and release 
after 15 minutes (rel15min) were taken as the response variables. 
A Simplex Centroid Mixture Design was selected for this 
experiment. It consists of 7 design points. This design generally involves 
independent variable X and dependent variables Y.  
The independent variables selected for this study were SSG 
(X1), CCS (X2) and PGS (X3) and dependent variables include 
Disintegration time (Y1) and Release at 15 min (rel15min) (Y2). The design 
of the MTCL immediate release layer with different variables is as given 
in table 2 and 3. Firstly 7 trial formulations were prepared. 
 
 
Table 2: Preparation of MTCL HCl Immediate Release Tablets 
(Design Mixture) 
Formulation 
Independent Variables* 
A B C 
M1 1 0 0 
M2 0 1 0 
M3 0 0 1 
M4 0.5 0.5 0 
M5 0.5 0 0.5 
M6 0 0.5 0.5 
M7 0.33 0.33 0.33 
Table 3: Coded level of MTCL immediate release formulation design 
and their actual values 
Coded level 
Actual values† 
A B C 
0 0 0 0 
0.33 4 4 4 
0.5 6 6 6 
1 12 12 12 
Table 4: Composition of MTH immediate release Tablet 
Formulations M1 M2 M3 M4 M5 M6 M7 
MTH 15 15 15 15 15 15 15 
SSG 12 - - 6 - 6 4 
CCS - 12 - 6 6 - 4 
PGS - - 12 - 6 6 4 
SLS 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Magnesium 
Stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 
MCC 70 70 70 70 70 70 70 
Total  100 100 100 100 100 100 100 
* Each values represented in mg 
*MTH: Metoclopramide Hydrochloride, SSG: Sodium starch glycolate, 
CCS: Cross carmellose sodium, PGS: Pre-gelatinized starch  
The raw materials were weighed (Table 4) and passed through 
85# screen prior to mixing. 90% Alcoholic solution of PVP was prepared 
and added to the mixture of MTH, sodium lauryl sulphate (SLS), 
intragranular fraction of superdisintegrants (50%) and microcrystalline 
cellulose. The granules were obtained by passing the mass through 16 # 
sieve. These granules were dried at room temperature for 2-3 hours and 
were again passed through 18 # sieve. The dried granules were mixed 
with the extra granular fraction (remaining 50%) of superdisintegrant 
and lubricated with required amount of magnesium state (2% w/w). The 
granules equivalent to 100 mg were compressed using a multi-station 
tablet compression machine (Rimek MINI, India) using 8 mm die [6, 7]. 
Composition of all batches was represented in Table 4. 
2.3 Data analysis 
Design-Expert Software version 7.0 was used to model the 
shape of the surfaces. After producing and analyzing the formulations, 
physical–chemical responses were applied to fit the appropriate model. 
The model was tested for goodness of fit (R2) and analysis of variance 
(ANOVA) was applied to verify the adequacy of the regression model in 
terms of a lack-of-fit test. Subsequently, grid search was performed to 
locate the composition of optimum formulations. Also, three-dimensional 
response surface graphs were drawn in MS-Excel using the output files 
generated by the Design Expert Software [8].  
2.4 Validation of Optimization Model 
Six optimum formulations (Table 5) were selected by grid 
search, performed over the entire experimental domain, to validate the 
chosen experimental design and polynomial equations. The criterion for 
selection of formulation was primarily based on the highest possible 
values of DT and rel15min. The formulation corresponding to these 
formulations were prepared and evaluated for various responses. The 
resultant experimental data of responses were subsequently 
quantitatively compared with the predicted values. Also, linear 
regression plots between observed and predicted values of the responses 
were attempted using MS- Excel, forcing the line through the origin.  
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Table 5: Composition of validated MTH immediate release layer  
(A1-A7)* 
Formulations F1 F2 F3 F4 F5 F6 
SSG 6.6 7.8 6.3 6.9 8.1 7.5 
CCS 5.4 4.2 5.7 5.1 3.9 4.5 
*All quantities are in mg 
*Each tablet contains MTH 15 mg, sodium lauryl sulphate 1.5 mg, 
microcrystalline cellulose 70 mg and magnesium stearate 1.5 mg. 
2.5 Formulation of Bilayered Tablet 
The bilayer tablet was prepared by taking the optimized 
formulation of the individual layers as studied earlier. 
Table 6: Optimized bilayer tablet 
Immediate 
Release Layer 
Quantity 
F6 
Conventional 
Release Layer 
Quantity 
A3 
MTH 15 ACF 66 
SSG 7.5 PVP K-30 12 
CCS 4.5 MCC 7 
SLS 1.5 Cab-o-sil 2 
Magnesium 
Stearate 
1.5 Magnesium 
Stearate 
2 
MCC 70 Lactose 11 
Total 100 Total 100 
The optimized formulation of conventional release tablet and 
immediate release tablet, i.e. F6 and A3 respectively was used to 
formulate bilayer tablet formulation. Both the formulations were 
prepared separately as described in experiment I and II, bilayer tablets 
were prepared by double compression technique.  
The compression was carried out on Rimek compression 
machine using 8 mm standard round flat punch set. First, previously 
weighed quantity of conventional layer blend was fed to die cavity as the 
first layer and compressed very slightly to get uniform layer, then 
weighed quantity of immediate layer blend was fed to the die cavity as 
the second layer and compressed finally to get bilayer tablet. By this 
method, the immediate release layer was compressed once, so there is 
fast disintegration and avoidance of the double compression.  
2.6 Evaluation of Bilayered Tablet 
The prepared bilayer tablets were evaluated as per standard 
procedure for hardness (n=3), weight variation (n=20), thickness (n=20), 
friability and drug content [9, 10]. Hardness of the tablets was tested 
using a Strong-Monsanto tablet hardness tester. Friability test was 
conducted using Roche friabilator. The thickness of the tablets was 
measured by digital Vernier caliper. Drug content was analyzed by 
measuring the absorbance of standard and samples at λmax 292 nm 
(Aceclofenac) and 248 nm (Metoclopramide Hydrochloride) using 
UV/Visible spectrophotometer (Shimadzu UV-1700). 
2.7 In vitro dissolution study 
In vitro dissolution study was carried out using the following 
operating variables. The in vitro release study for all formulations was 
carried out in dissolution rate test apparatus.  
Apparatus                  : USP dissolution apparatus type 2 (paddle type) I.P. 
Speed of the paddle : 75 rpm 
Temperature             : 37°C + 0.5°C 
Dissolution medium: 
Acid stage: 900 ml 0.1 N Hydrochloric acid for 1 hr. 
Buffer stage: 900 ml phosphate buffer of pH 6.8 for next subsequent 
hours. 
One tablet previously weighed, was kept in the dissolution 
medium. 10 ml samples were withdrawn at half hour intervals, filtered 
and was diluted to 10 ml and analyzed by using UV-spectrophotometer 
(JASCO V-530) at specified wavelength (nm). Aliquots of sample removed 
were replaced with fresh dissolution medium. The absorbances were 
noted down for each aliquot. The concentration was calculated by using 
the software PCP Disso v2.08. 
2.8 Dissolution study of marketed formulation 
The dissolution study of the marketed formulation  (ACECLO, 
ARISTO Pharma Ltd. Mumbai) was carreid out to study the release 
pattern of tablet. 
 
3. Results and Discussion  
3.1 Physical Properties 
The following parameters were evaluated (Table 7) for the 
MTH, ACF, SSG, CCS, PGS, Lactose and microcrystalline cellulose (MCC).  
Table 7: Physical properties of drug and excipients 
Material Bulk Density (gm/ml) Tapped Density (gm/ml) Angle of Repose (θ) Carr’s Index (%) Hausner Ratio 
MTH 0.29 0.231 17.37 1.209 26.12 
ACF 0.25 0.280 10.71 1.120 30.21 
SSG 0.24 0.290 17.10 1.209 25.74 
CCS 0.22 0.246 19.24 1.210 27.64 
PGS 0.23 0.264 12.24 1.120 24.21 
Lactose 0.25 0.314 17.19 1.300 27.21 
MCC 0.26 0.230 19.49 1.360 28.13 
3.2 ACF Conventional Release Layer 
1) Blend property 
The prepared granules were evaluated for the blend property like 
bulk density, tapped density, Carr’s index [11], Hausner ratio and angle of 
repose [12]. 
The Carr’s index of A1 was 12.95% while maximum was 20.05% for 
A8 formulation i.e. in the range of 10-20% which was considered as 
excellent to good flow property. Angle of repose less than 30° gives good 
flow property to the granules. All the formulations except A7 and A8 had 
an angle of repose of less than 30° indicating flow ability of granules 
(Table 8). This may be due to the concentration of the binder PVP K-30. 
The bulk density of all the formulation was in the range of 0.289 to 0.399. 
Hausner ratio of all formulation was below 1.5 indicates good 
compression characteristics. All the parameters were inter related to the 
tablet properties like hardness, friability etc. All these results indicate 
(Table 8) that, the granules possess satisfactory flow and compressibility 
properties.
Table 8: Blend properties of formulation of ACF conventional release layer 
Formulations Bulk Density (gm/ml) Tapped Density (gm/ml) Carr’s Index (%) Hausner Ratio Angle of Repose (θ) 
A1 0.289 0.332 12.95% 1.148 24.54 
A2 0.339 0.364 14.36% 1.073 21.89 
A3 0.294 0.389 16.23% 1.323 24.10 
A4 0.321 0.362 12.77% 1.127 25.54 
A5 0.295 0.364 18.95% 1.233 28.61 
A6 0.293 0.355 17.46% 1.211 29.78 
A7 0.299 0.354 15.53% 1.183 33.36 
A8 0.308 0.366 20.05% 1.188 32.73 
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2) Evaluation of ACF Conventional Release Tablet 
The compressed tablets were subjected for the test like thickness, hardness, tensile strength, friability, and disintegration time and % drug 
content. The results are as follows; 
Table 9: Tablet properties of formulation of ACF conventional release layer 
Formulations Thickness (mm) Hardness (Kg/cm2) % Friability Disintegration Time (min) % Drug  Content 
A1 1.2 ± 0.3 3-4 1.249 0.53 99.23 ±1.7 
A2 1.2 ± 0.5 3-4 1.009 1.12 99.57±0.35 
A3 1.2 ± 0.1 3-4 0.525 1.59 99.68±0.48 
A4 1.2 ± 0.4 3-4 0.496 2.13 99.23±0.45 
A5 1.2 ± 0.3 3-4 0.556 3.56 101.23±0.25 
A6 1.2 ± 0.4 3-4 0.493 5.29 98.53±0.49 
A7 1.2 ± 0.1 3-4 0.413 8.17 99.31±0.15 
A8 1.2 ± 0.3 4-5 0.493 11.26 101.44±0.74 
ACECLO 
(Marketed) 
2.2 ± 0.1 3-4 - 1.43 101.67±0.57 
 
According to above data, all the formulations showed uniform 
thickness. In weight variation test, the pharmacopoeial limit for the 
percentage deviation for tablets of more than 200 mg is ±5%. Good 
uniformity in drug content was found among different batches of the 
tablets, and the percentage of drug content was between 95-105%. 
The % friability for all the formulations was below 1%, 
indicating that the friability is within the prescribed limits.  All forms 
complied with the in-house specifications for weight variation, drug 
content, hardness, and friability. 
3) In vitro dissolution study 
The dissolution was carried in two parts 
 0.1N HCl for first hour 
 Phosphate buffer pH 6.8 for next subsequent hours 
The release of ACF conventional release layer mainly depends on 
the quantity of binder PVP K-30 and disintegrant Micro-crystalline 
cellulose (MCC). The concentration range of PVP K-30 was 1-8% while 
that of MCC was 8-12%. 
Comparable release rates for the tablets based on the different 
ratio of binder as well as disintegrant were obtained for the period of 2.5 
hrs. From the dissolution profile of tablet as shown in Fig 8, it can be 
concluded that, the formulation A3 which showed %CDR of 99.51% 
which was selected for preparation of optimized formulation. Also it has 
f2 value of 68.23 with the marketed formulation which resembles its 
similarity factor. The reason for this is use of optimum quantity of binder 
(7%) and disintegrants (12%). Low concentration of binder causes 
tablets to be friable and also it does not show a release pattern similar to 
that of marketed type (A1 and A2). On the other hand, higher the 
concentration of binder causes the tablet take longer time to disintegrate 
and hence slowing the release of the drug (93-94%) in 2.5 hrs for A6-A8. 
From the dissolution profile, it was observed that the release of 
drug ACF in 0.1N HCl is very poor i.e. it releases the drug upto 2-3% 
which is very negligible. But when the dissolution medium was changed 
to phosphate buffer pH 6.8, there was a significant change in release 
profile, which showed a steep increase. This is also the reason why 
NSAID’s show maximum absorption in the intestine. 
 
Table 10: % Cumulative drug release profile of ACF conventional release layer 
Time 
(Hrs) 
A1 A2 A3 A4 A5 A6 A7 A8 
ACECLO 
(Marketed) 
0 0 0 0 0 0 0 0 0 0 
1 3.56 3.51 4.05 4.56 2.21 2.03 1.96 2.11 3.40 
1.5 45.77 43.75 46.81 44.32 41.29 39.45 38.16 39.46 44.04 
2 79.13 71.32 72.16 69.23 67.28 65.09 66.34 65.91 69.19 
2.5 102.83 100.03 99.51 98.26 97.61 94.37 95.38 93.15 99.84 
 
 
Fig 1: % drug release of ACF conventional layer (A1-A8) 
 
Fig 2: Comparison of the optimized formulation with ACECLO 
(marketed) 
3.3 MTH Immediate Release Layer 
1) Blend Property 
All the formulations were evaluated for the blend property like bulk density, tapped density, compressibility index and Hausner ratio. 
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Table 11: Blend properties of MTH Immediate release layer 
Formulation Bulk Density (gm/ml) 
Tapped Density 
(gm/ml) 
Angle of Repose (θ) Carr’s Index (%) 
Hausner 
Ratio 
M1 0.418 0.469 21.75 10.87 1.122 
M2 0.438 0.521 22.86 15.93 1.189 
M3 0.421 0.482 26.04 12.65 1.144 
M4 0.431 0.504 28.27 14.48 1.169 
M5 0.427 0.499 27.20 14.42 1.168 
M6 0.435 0.517 25.69 15.86 1.188 
M7 0.459 0.532 30.04 13.72 1.159 
 
The above result predicts that, the Carr’s index of all the 
formulations was in the range of 10-15% which was considered as 
excellent flow property. Angle of repose less than 30° gives good flow 
property to the granules and all formulations have angle of repose less 
than 30°. Hausner ratio of all formulations was below 1.5 gives good 
compression characteristics. All these results indicate that, the granules 
possess satisfactory flow and compressibility properties. 
 
 
 
2) Evaluation of MTH Immediate Release Tablet 
MTCL immediate release tablet was evaluated for the physical 
parameters like thickness, hardness, friability, disintegration time (DT), 
wetting time and uniformity of weight. 
The obtained results of above evaluation test are depicted in table 12. 
The immediate release tablet of MTH was evaluated and above 
result predicts that, all the formulations were found to exhibit 
satisfactory tablet properties. The disintegration time of tablet ranged 
from 9-22 sec in which formulation M4 containing SSG & CCS in equal 
proportions was found to have minimum DT of 9 sec. 
Table 12: Tablet properties of formulation of MTH immediate release layer 
Formulation Thickness (mm) Hardness (kg/cm2) % Friability DT (Sec) Wetting Time (Sec) % Drug Content 
M1 0.6 2-3 0.198 12 3.17 99.23±0.17 
M2 0.6 2-3 0.2 15 3.42 99.45±0.02 
M3 0.6 2-3 0.261 22 4.89 99.18±1.08 
M4 0.6 2-3 0.176 9 3.04 99.56±1.12 
M5 0.6 2-3 0.148 18 4.56 98.79±0.56 
M6 0.6 2-3 0.211 16 4.08 99.08±0.73 
M7 0.6 2-3 0.357 13 3.97 98.90±1.15 
 
The mechanism of action of SSG is rapid uptake of water 
followed by rapid and enormous swelling, whereas CCS acts by the way 
of wicking and swelling ability.  
The mechanism of disintegration was considered to be by 
drawing water into the tablet, swelling and causing the tablet to burst 
apart. As the drug has excellent water solubility, dissolution will not be 
rate limiting.  
The formulation with SSG, CCS or PGS separately showed 
greater disintegration time as compared to the formulation M4 
containing SSG and CCS in combination. M1 had showed less DT than M2 
which indicates that concentration of SSG in the formulation is more 
pronounced to reduce the DT with CCS. M3 which contains only PGS had 
showed very poor profile as its DT is 22 sec which gives the significance 
that comparatively it is poor superdisintegrant. M7 have DT of 13 second 
and wetting time of 3.97 seconds as it contains all the three super-
disintegrants. 
The incorporation of wetting surfactant SLS favored the 
disintegration of the tablet by decreasing the interfacial tension and 
aiding absorption of water by forming the pores in tablet.  
Wetting time: The wetting time gives out the significance of 
time required for the tablet to acquire moisture and also the minimum 
volume of liquid required for it. The tablets with combination of SSG and 
CCS had shown minimum time (3.04) to acquire moisture while the tablet 
with PGS only had shown maximum time (4.89). 
3) In vitro release studies of immediate release layer  
Different formulations with varying amount of drug: 
disintegrant ratios, employing wet granulation technique for immediate 
release layer were formulated. The in vitro release data is as follows: 
 
 
 
 
 
Table 13: Dissolution profile of MTH immediate release tablet 
TIME 
(min) 
M1 M2 M3 M4 M5 M6 M7 
0 0 0 0 0 0 0 0 
3 43.38 34.97 37.22 55.31 43.33 52.56 47.45 
6 51.62 53.98 55.79 63.53 59.92 62.04 61.46 
9 65.066 66.23 67.54 78.24 75.36 74.91 75.12 
12 82.42 83.12 77.67 87.96 87.63 80.29 81.94 
15 95.229 92.75 87.05 98.31 89.84 91.24 93.89 
 
From the dissolution profile of immediate release layer tablet 
formulation (M1-M7), as shown in table 13 and in Fig. 3, it was concluded 
that formulation M4 was considered to be the optimized formula, as it 
had highest % CDR of 98.31% of all formulations. This may be attributed 
to combination of two superdisintegrants like SSG and CCS along with the 
diluents MCC which also acts as a disintegrant. M3 had shown least CDR 
of 87.05%. The obvious reason may be the use of pregelitanized starch 
which showed poor superdisintegrants property. The combination of 
both the superdisintegrants showed good disintegrant behavior. It 
showed complete dissolution within 15 minutes. The formulation M7 
containing mixture of all three superdisintegrants showed 93.89% drug 
release in 15 minutes. 
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Fig 3: % Drug Release of MTH Immediate Release layer (M1-M7) 
4) Analysis of Variance of the Super Cubic Model for the Responses 
Screening is used in the beginning of the experimental 
procedure for investigating large numbers of factors aiming to reveal the 
most important among them. Optimization is applied for finding a factor 
combination matching an optimal response profile. The design 
supporting a linear model is useful when the experimental objective is 
screened.   
Table 14: Analysis of variance of the super cubic model for the 
responses 
Model Disintegration time rel15min 
R2 0.9907 0.9676 
F value 85.35 14.94 
The above value predicts that, the super cubic model is best 
fitted model for the mixture design. The value of R2 was near to 1 which 
signifies that, formulations were following the Super Cubic model. The 
other two models as linear and quadratic does not give the significant 
values for both the parameters as DT in sec and rel15min. 
From the above data, coordinate system for the mixture design 
is called a simplex coordinate system. With three components (SSG, CCS, 
PGS) the coordinate can be plotted on a triangular graph.  
5) RSM Optimization Results 
3.4 Mathematical Modeling 
Mathematical relationships generated using ANOVA for the 
studied response variables are expressed as equation 1 and 2. 
 
DT=11.52A+15.52B+22.52C-18.76AB-4.76AC-4.76BC-8.24ABC              (1) 
 
rel15min=95.84A+92.00B+86.23C+18.79AB+1.66AC+3.45BC-6.04ABC   (2) 
 
All the polynomial equations were found to be statistically 
significant (P<0.01), as determined using ANOVA, as per the provision of 
Design Expert software shown in Table 14. The polynomial equation 
comprises of the coefficient for intercept. The sign and magnitude of the 
main effects signify the relative influence of each factor on the response. 
In the eq. 1, (-) sign indicates decrease in DT. From the eq. 1, the 
formulations with compositions AB, AC, BC and ABC had showed the 
minimum DT as compared to formulations A, B and C. the coefficient 
value of each denotes DT in seconds. Coefficient of AB had lowest 
polynomial value of -18.76 which had lowest DT of 9sec whereas 
coefficient of C has the highest polynomial value of + 22.25 indicating 
higher DT of 22sec.  Coefficients of AC and BC had the same polynomial 
value of -4.76 indicating nearby same DT as 18 and 16 seconds 
respectively.  
In the eq. 2, the coefficient value depends upon the no. of 
variables i.e. A, B, and C. for the formulations containing single 
component had shown polynomial values above 85 in first three 
coefficient A have highest polynomial value 9 i.e. 95.84 will give highest 
% of drug as 95.22% while C will give lowest % drug release 87.05% as it 
has a polynomial value of 86.23. In the next three coefficients, there is 
mixture of two superdisintegrants. The polynomial value obtained for 
these coefficients are below 20 and coefficient AB has highest polynomial 
value of 18.79 which gives highest % drug release of 98.79%. The 
coefficient of formulation containing all the three superdisintegrants 
showed polynomial value in – 6.04 and having a % drug release of 
93.89% which is less than the formulation having coefficient AB.  
The value obtained for main effects of each factor in equation 1 
and 2 that is concentration of superdisintegrants as SSG (X1), CCS (X2) 
and PGS (X3) used separately or in combination has rather more 
pronounced effect on DT (Y1) as well as rel15min (Y2).  The use of X1 and X2 
in combination has given the prominent results for the factors Y1 and Y2.  
At a given set of factor levels however, these higher-order polynomials 
yield results as the net effect of all the coefficient terms contained in the 
polynomial. In equation 2, the value predicts the release of the drug. In 
combination the coefficient value of AB is highest giving the higher % 
drug release.  
3.5 Response Surface Analysis  
Response surface diagrams illustrating model equations and 
showing the effects of superdisintegrants on DT and rel15min of MTCL IR 
tablets were created to interpret the mixture region (Fig 4 and 5). In the 
response surface, each factor (pure mixture component) is represented 
in a corner of an equilateral triangle; each point within this triangle 
refers to a different proportion of components in the mixture. The 
maximum percentage of each ingredient considered by the regression is 
placed at the corresponding corner while the minimum is positioned at 
the middle of the opposite side of the triangle.  
In the diagram, (Fig 4) the DT was decreased for X1 and X2 as 
compare to X3; the apex point of triangle for X3 goes upward denoting 
increased DT. On the other hand, the use of these parameters in 
combinations as X1X2, X2X3, and X1X3 also showed different DT denoted 
on the side of triangle. The lowest value obtained for the combination of 
X1X2 as 9 seconds. The inclination of curves in Fig 4 shows that effect of 
X1 is more pronounced to reduce the DT than that of X2.  
 
 
Fig 4: Response surface diagram and contour plot diagram for DT  
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The above triangular countour plot diagrams for DT indicates 
that the concentration of the superdisintegrant in the blue colored region 
gives the minimum DT i.e. less than 10.936 sec. whereas the 
concentration of superdisintegrant in the orange colored region gives DT 
more than 20.2041 sec. 
Fig 4 showing the release of drug after 15 min shows highest 
possible release for the combination X1X2 of 98.311%, while the lowest 
release value obtained for X3 of 87.05%.  The curve seems to be inclined 
towards C which indicates that, the release profile of PGS is poor as 
compares to SSG and CCS.  
 
 
Fig 5: Response surface plot and contour plot diagram for Rel at 15 
min. 
 
The contour plot diagrams in Fig 5 for Rel at 15 min indicates, 
the red colored region having maximum % drug release i.e. above 
96.718% where the concentration of SSG and CCS is more, while the blue 
colored region gives minimum % drug release of less than 88.3276%. 
3.6 Search for the Optimum Formulation 
The optimum formula for MTH immediate release layer was 
searched by grid search. Varying the concentration of the 
superdisintegrant, the following results were obtained.  
Table 15: Feasibility Search for the MTH immediate release tablet 
for response variables as DT and release at 15 min. (Region I) 
DT (Seconds) 
SSG CCS PGS DT (Sec) SSG CCS PGS DT (Sec) 
0 1 0 15.52 0 0.8 0.2 16.1584 
0.2 0.8 0 11.7184 0 1 0 15.52 
0.4 0.6 0 9.4176 0.6 0 0.4 14.7776 
0.6 0.4 0 8.6176 0.4 0 0.6 16.9776 
0.8 0.2 0 9.3184 0.2 0 0.8 19.5584 
0.7 0.3 0 8.7804 0 0 1 22.52 
0.5 0.5 0 8.83 0.6 0.2 0.2 11.5072 
1 0 0 11.52 0.3 0.7 0 10.3804 
0 0 1 22.52 0.6 0.3 0.1 10.0148 
0 0.2 0.8 20.3584 0.9 0.1 0 10.2316 
0 0.4 0.6 18.5776 0.85 0.15 0 9.7281 
0 0.6 0.4 17.1776 1 0 0 11.52 
 0.8 0 0.2 12.9584 
Rel at 15 min 
SSG CCS PGS Rel at 15 min SSG CCS PGS Rel at 15 min 
0 1 0 92 0 0.8 0.2 91.398 
0.2 0.8 0 95.7744 0 1 0 92 
0.4 0.6 0 98.0456 0.6 0 0.4 92.3944 
0.6 0.4 0 98.8136 0.4 0 0.6 90.4724 
0.8 0.2 0 98.0784 0.2 0 0.8 88.4176 
0.7 0.3 0 98.6339 0 0 1 86.23 
0.5 0.5 0 98.6175 0.6 0.2 0.2 95.59704 
1 0 0 95.84 0.3 0.7 0 97.0979 
0 0 1 86.23 0.6 0.3 0.1 97.20358 
0 0.2 0.8 87.936 0.9 0.1 0 97.1471 
0 0.4 0.6 89.366 0.85 0.15 0 97.659725 
0 0.6 0.4 90.52 1 0 0 95.84 
 0.8 0 0.2 94.1836 
        Optimized formulations 
 
Table 16: Feasibility Search for the MTH immediate release tablet 
for response variables as DT and release at 15 min with Region I 
values. (Region II) 
DT in seconds 
SSG CCS PGS DT (Sec) SSG CCS PGS DT (Sec) 
0.45 0.55 0 9.0769 0.775 0.225 0 9.148725 
0.55 0.45 0 8.6769 0.45 0.55 0 9.0769 
0.65 0.35 0 8.6521 0.35 0.65 0 9.8521 
0.75 0.25 0 9.0025 0.25 0.75 0 11.0025 
0.525 0.475 0 8.741725 0.475 0.525 0 8.941725 
0.425 0.575 0 9.235525 0.275 0.725 0 10.679725 
0.725 0.275 0 8.879725 0.425 0.575 0 9.235525 
0.475 0.525 0 8.941725 0.325 0.675 0 10.104525 
0.575 0.425 0 8.635525 0.375 0.625 0 9.623125 
0.675 0.325 0 8.704525 0.225 0.775 0 11.348725 
0.625 0.375 0 8.623125     
Rel at 15 min 
SSG CCS PGS Rel at 15 min SSG CCS PGS 
Rel at 15 
min 
0.45 0.55 0 98.378525 0.775 0.225 0 98.25250625 
0.55 0.45 0 98.762525 0.45 0.55 0 98.378525 
0.65 0.35 0 98.770725 0.35 0.65 0 97.618725 
0.75 0.25 0 98.403125 0.25 0.75 0 96.483125 
0.525 0.475 0 98.70175625 0.475 0.525 0 98.50975625 
0.425 0.575 0 98.22380625 0.275 0.725 0 96.80225625 
0.725 0.275 0 98.53025625 0.425 0.575 0 98.22380625 
0.475 0.525 0 98.50975625 0.325 0.675 0 97.37005625 
0.575 0.425 0 98.79980625 0.375 0.625 0 97.84390625 
0.675 0.325 0 98.71405625 0.225 0.775 0 96.14050625 
0.625 0.375 0 98.80390625     
 
      Optimized formulations 
 
3.7 Optimization 
The process was optimized for the response DT (Y1) and 
rel15min (Y2.) For selection of optimum formulations the following 
maximizing criteria was adopted: rel15min>97%; DT<9 sec. Upon the 
subsequently exhaustive grid searches, the formulation composition with 
superdisintegrants levels of SSG (X1) and CCS (X2) fulfilled maximum 
requisites of an optimum formulation due to better regulation of release 
rate and minimum DT. The formulations showed rel8h as 98.67 and 
8.86sec as DT. 
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6)  In vitro dissolution study of optimized formulation  
The dissolution study of optimized formulation of MTH 
immediate release tablet was carried out in 0.1N HCl. The results were as 
follows 
Table 17: Dissolution profile of optimized formulation of MTH 
immediate release tablet 
TIME (min)  F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
3 54.75 57.84 55.39 57.05 54.15 56.75 
6 61.12 64.81 62.26 64.84 60.20 64.31 
9 73.80 75.36 74.67 78.24 72.51 77.92 
12 84.75 88.18 85.78 87.08 84.00 86.92 
15 98.34 98.52 97.98 98.64 98.03 98.70 
 
Fig. 6: % drug rel 15min of optimized formulation (F1-F6) 
From Table 17 and Fig 6 it is evident that, formulation F6 
containing 7.5mg SSG and 4.5mg CCS gave maximum drug release i.e. 
98.70% within 15 minutes whereas formulation F3 containing 6.3mg SSG 
and 5.7mg CCS showed % of drug release of 97.98% within 15 minutes. 
Table 18 indicates that, the concentration of SSG in the range of 6.9mg to 
7.8mg while concentration of CCS in the range of 4.2mg to 5.1mg in 
combination will give the minimum DT with higher % of drug release.    
7) Validation of optimized formulations 
For all 6 checkpoint formulations, the results of the physical 
evaluation and tablet assay were found to be within limits. Table 18 lists 
the composition of the checkpoints, their predicted and experimental 
values of all the response variables, and the percentage error in 
prognosis. Validation was carried out by verifying the predicted values 
obtained from the software with the experimental values of the 
optimized formulations and percent error mean was calculated. Fig. 7 
and 8, shows linear correlation plots between the observed and predicted 
response variables, the residual plots showing the scatter of the residuals 
versus observed values. The linear correlation plots drawn between the 
predicted and observed responses demonstrated higher values of r2 
(ranging between 0.9726 and 0.9811), indicating excellent good fitting of 
model (P<0.001). Upon validation, the optimum formulations exhibited 
percentage error for various response variables, varying 2.70 to 4.505% 
(DT) and -0.734 to -0.101 % (rel15min). Thus, the low magnitudes of error 
as well as the significant values of r2 in the current study indicate a high 
prognostic ability of RSM for MTH IR tablet. 
An optimized formulation F6 of immediate release tablets was 
found to give minimum disintegration time (8.62 sec) and higher drug 
release at 15 minutes (98.67 %) which will give ready onset of action. 
The higher value of SSG in combination with CCS gave out better result. 
Design and analysis of experiments were used as good tools to obtain the 
optimal formulation, which showed minimum friability, no lamination 
and that also met all official pharmaceutical specifications. 
The validated data of the optimized formulation is given in 
table 18. 
Table 18:  Validation of optimized formulation 
Composition 
Dependant 
Variable 
Experimental 
Value 
Predicted 
Value 
Percentage 
Error 
X1 
(mg) 
X2 
(mg) 
6.6 5.4 
DT 9.10 8.67 4.505 
rel15min 98.34 98.76 -0.427 
7.8 4.2 
DT 9.01 8.65 3.99 
rel15min 98.52 98.77 -0.253 
6.3 5.7 
DT 9.12 8.74 4.166 
rel15min 97.98 98.70 -0.734 
6.9 5.1 
DT 8.89 8.63 2.92 
rel15min 98.64 98.79 -0.101 
8.1 3.9 
DT 9.15 8.70 4.91 
rel15min 98.03 98.71 -0.693 
7.5 4.5 
DT 8.86 8.62 2.70 
rel15min 98.67 98.80 -0.131 
* DT Disintegration time, rel15min Drug release at 15 min  
 
Fig 7: Graph of experimental v/s predicted values of DT F1-F6 
formulation. 
 
Fig 8: Graph of experimental v/s predicted values of rel15min of 
optimized formulations. 
3.8 Bilayer Tablet of ASF and MTH 
1) Properties of bilayer tablet 
The tablet was evaluated for the physical parameters like 
thickness, hardness, % friability and DT. It was also checked for capping 
and lamination problem. There was no capping and lamination for any 
formulations. 
Thickness of bilayer tablet was found to be decrease due to 
double compression pressure. Hardness was found to be within the 
range. 
Table 19: Tablet properties of bilayer tablet formulation 
Formulation 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
% Friability DT in sec. 
AF* 1.7 4-5 0.66 131 
A 1.2 3-4 - 122 
F 0.6 1-2 - 9 
*A = conventional release layer and F = immediate release layer 
 % friability was below 1% and it was found to decrease for bilayer 
tablet because of double compression. DT of bilayer tablet was found to 
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be 131 sec inclusive of immediate release layer and conventional release 
layer. Above data concludes that, there is no interference of double 
compression pressure on the properties of bilayer tablet.  
2) In vitro dissolution study of bilayer tablet  
 The dissolution of the bilayer tablet was carried out in two 
steps as described in the experimental. The results are as follows.  
 
Table 20: Comparison of dissolution profile of MTH of bilayer tablet 
with F6 formulation. 
Time 
(Minutes) 
% Cumulative Drug Release (% CPR) 
Bilayer Tablet F6 
0 0 0 
3 58.69 56.75 
6 62.69 64.31 
9 80.58 77.92 
12 88.92 86.92 
15 99.26 98.70 
 
 
Fig 9: Comparison of dissolution profile of MTH of bilayer tablet 
with F3 formulation. 
 
On comparing the release profile of MTH from immediate 
release layer of bilayer tablet formulation with formulation F6 (Fig 9), 
higher values for % cumulative drug release of 99.26% of MTH was 
observed   
Similarly, the dissolution profile of ACF of bilayer tablet was compared 
with the optimized A3 formulation and results are as shown below. 
 
Table 21: Comparison of dissolution profile of ACF of bilayer tablet 
with A3 formulation. 
Time  
(Hours) 
% Cumulative Drug Release (% CPR) 
A3 Conventional layer of bilayer tablet 
0 0 0 
1 4.05 3.26 
1.5 46.81 44.34 
2 72.16 68.09 
2.5 99.51 98.03 
From Fig 10, it was observed that the drug release profile 
decreases somewhat (98.03%) for the ACF conventional release layer of 
bilayer tablet as that of the formulation A3 with similar composition due 
to the double compression on the lower layer of bilayer tablet. In the first 
hour there was only 3-4% drug release from the conventional layer of 
bilayer tablet which is due to the dissolution medium 0.1N HCl. 
 
Fig 10: Comparison of dissolution profile of ACF of bilayer tablet 
with A3 formulation. 
From the dissolution profile of the bilayer tablet, dissolution 
being conducted in two parts as described earlier, the formulation gives 
almost same results. The formulation did not show any capping or 
lamination. The reason for this could be the use of easily fragmenting 
materials like lactose and MCC. Thus volume reduction by fragmentation 
seems to be more efficient means of producing larger surface areas that 
will promote inter-particulate attraction in the compacts. Interfacial 
bonds formed between two layers are strong. Thus high fragmentation of 
tablet components will facilitate the formation of mechanically strong 
bilayer tablets. 
3.9 Stability Studies  
1) Physical changes 
The mixture which was subjected to stability study at 
40°C/75%RH shows brown discoloration (Fig 11) at the end of 45 days 
indicating photo-oxidative degradation of the sample. The data is 
supported by FT-IR, DSC and quantitative analysis. 
 
(A) 
 
(B) 
Figure 11: Photograph of samples of physical mixture (ACF + MTH) 
at (A) 0 days and at (B) 45 days 
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2) FT-IR study  
In the FT-IR study, the samples  ACF, MTH, physical mixture at 
0 days and physical mixture at 45 days were checked at 1st , 28th, and 45th 
day. The results were as follows 
 
 Green color – Day 1st             
 Brown color – Day 28 
 Blue color – Day 45th 
Figure 12: FT-IR spectrum of physical mixture subjected to stability 
study 
 
Table 22: Comparison of the IR spectra of MTH and ACF for physical 
mixture subjected to stability study 
MTH 
 IR Ranges Day  1st Day 28th Day  45th 
3200 + + - 
3300 + + + 
2860 + - - 
2500 + + - 
1600 + + + 
1540 + + - 
1270 + - - 
700 + - - 
ACF 
3318 + + + 
1717 + + + 
1590 + + - 
1507 + + + 
750 + + + 
717 + + + 
 
From the above results it can be concluded that, the 
degradation of the physical mixture was mostly checked at 1st, 28th and 
45th day. MTH is getting more degraded as its characteristics peaks like 
3200, 2500, 1540 (N-H), 3340 (O-H), 2860 (C-H), 1270 (C-O-C), 700 (C-
Cl) are absent while only 2 peaks as 3300 (N-H) and 1600 (C=O) are 
present at the 45th day. In the spectra of ACF, only one peak as 1590 (N-H 
deformation) is absent at the 45th day. This concludes that, there is 
degradation of both the drugs and MTH getting more degraded as 
compare to ACF in the acidic environment. NH bonding was found to be 
mainly affected in the IR spectra of physical mixture of both the drugs 
which confirms that there is complex of the amino group with other 
acidic moiety.  
The IR spectra of bilayer tablet had shown all the prominent 
peaks of both the drugs are present at the end of 45th day, which confirms 
that bilayer tablet does not show any degradation of the tablet and 
confirms its stability (Fig 13). 
 
 Green color – Day 1st             
 Brown color – Day 28 
 Blue color – Day 45th 
Fig 13: FT-IR spectrum of bilayer tablet at different days intervals  
 
3) DSC study 
The differential scanning colorimetry study was carried out on 
the four samples to study the degradation of the drug. The obtained 
results were as follows. 
 
Fig 14: DSC thermogram of (a) ACF, (b) MTH, (c) physical mixture 
and (d) sample subjected to stability 
 
In the DSC analysis, samples were subjected to thermal study 
to check the degradation of sample. 
The thermogram of pure ACF showed a single sharp 
endothermic peak at 153.25ºC with an onset temperature of 152.42 ºC 
with the peak width of 1.28 ºC which confirms its purity. MTH also 
showed its sharp endothermic peak at 94.90 ºC which is its melting point 
with an onset temperature of 92.17 ºC confirming its purity. In the 
physical mixture (PM) at 0 day, both the drugs showed the characteristic 
sharp endothermic peaks at their respective melting points i.e. 152.84 ºC 
and 95.15 ºC of ACF and MTH respectively which is approximately 
similar to the peaks obtained for pure drug as described earlier. The 
thermogram of PM at 45 days showed broadening as well as shifting of 
the peak at 143.93 ºC with onset temperature 132.97 ºC for ACF and 
85.81 ºC with onset temperature 74.99 ºC for MTH. The height of the 
peak of both the drugs in the PM at 45th day was found to be decreased as 
shown in Fig. 15.  
The thermal characteristics of samples are summarized in 
table 23. 
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Table 23: Thermal characteristics of samples 
Sample Onset 
(To°C) 
Peak 
(Tp°C) 
Endset 
(Te°C) 
Peak 
width (°C) 
ACF 152.42 153.25 154.16 1.28 
MTH 92.17 94.90 97.41 2.96 
Physical 
mixture 
(0 days) 
ACF – 
151.05 
ACF – 
152.84 
ACF-
153.87 
ACF –  
1.48 
MTH – 
92.02 
MTH – 
95.15 
MTH – 
97.56 
MTH – 
 3.21 
Physical 
mixture 
(45 day) 
ACF – 
132.97 
ACF – 
143.93 
ACF – 
151.50 
ACF – 
12.79 
MTH – 
74.99 
MTH – 
85.81 
MTH – 
91.68 
MTH –  
9.92 
 
The peaks have almost disappeared. There was a change in the 
peak width of both the drugs. The peak width of ACF was found to have 
changed drastically as mentioned in Table 15. 
 
Fig 15: DSC thermogram of physical mixture (PM) at 45th day 
 
Also one exothermic peak was observed which may be due to 
oxidative degradation of the mixture (Fig 15).  
The above all data predicts that, there is degradation of the 
drug in the sample which was subjected to stability study. The 
degradation might be due to the amide group of MTH with the carboxylic 
group of ACF.     
 
4) Quantitative analysis of samples:  
The % drug content study was carried out to study the 
degradation of the drug quantitatively. The physical mixture and bilayer 
tablet were evaluated for % drug content at the time interval of 7, 14, 21, 
28, 45 day. In the present study quantification was carried out at two 
different conditions as  
 At ambient conditions 
 At 40°C/75% RH 
 
Table 24: Quantitative % degradation of the physical mixture and 
bilayer tablet at 40°C/75% RH 
Time 
(Days) 
% Purity (At 40°C/75% RH) 
ACF† MTH‡ Bilayer Tablet Physical Mixture 
7 99.79 99.61 ACF-99.29 ACF-99.09 
MTH-99.16 MTCL-99.52 
14 99.57 99.48 ACF-99.21 ACF-98.46 
MTH-99.10 MTCL-98.07 
21 99.63 99.27 ACF-99.37 ACF-93.32 
MTH-99.25 MTCL-92.67 
28 99.59 99.10 ACF-99.46 ACF-87.35 
MTH99.07 MTCL-79.48 
45 99.48 99.31                                                                                                                                                        ACF-99.31 ACF-82.17 
MTH-98.81 MTCL-74.09 
 
Table 25: Quantitative % degradation of the physical mixture and 
bilayer tablet at ambient temperature 
Time 
(Days) 
% Purity (At ambient temperature) 
ACF† MTH‡ Bilayer tablet Physical mixture 
7 99.83 99.77 ACF-99.53 ACF-99.67 
MTH-99.60 MTH-99.28 
14 99.71 99.74 ACF-99.36 ACF-99.07 
MTH-99.52 MTH-96.22 
21 99.65 99.68 ACF-99.31 ACF-93.43 
MTH-99.58 MTH-87.59 
28 99.69 99.73 ACF-99.38 ACF-87.57 
MTH99.49 MTH-80.19 
45 99.72 99.54 ACF-99.45 ACF-85.71 
MTH-98.96 MTH-77.34. 
 
The above result (Table 24 and 25) concludes that, there was 
not a significant change in the value of % drug content of ACF as well as 
MTH at the 7th day and at 45th day which indicates stability of drug under 
given conditions. In the evaluation of bilayer tablet, the % drug content of 
ACF at 7th day was found to be 99.29% whereas and at the 45th day it was 
99.31% while % drug content of MTH at 7th day was 99.16% and 98.81% 
at 45th day which is not a very significant change confirming the stability 
of bilayer tablet for longer period. Results of PM had changed 
significantly. The % drug content of ACF was changed from 99.09% to 
82.17% at 7th and 45th day respectively whereas % drug content of MTH 
was found to be changed from 99.52% to 74.09%. This significant change 
predicts that, there is degradation of the physical mixture while the 
bilayer tablet formulation was found to be stable [13-18].  
 
4. Conclusion 
In ACF conventional release layer, maximum drug release is 
achieved in 2.5 hrs. Conventional layer release very low amount of drug 
in 1st hour i.e. 3-4 % in 0.1N HCl. Different concentrations of PVP K-30 as 
binder and MCC as disintegrant were used to formulate the conventional 
layer which showed different release pattern. The concentration of PVP 
K-30 significantly affected the release pattern of the drug than that of 
MCC which acts as disintegrant. Formulation A3 having PVP K-30 (7%) as 
binder and MCC (12%) as disintegrant had shown 99.15 % drug release 
in 2.5 hrs. The optimized formula was compared with marketed 
formulation ACECLO (ARISTO Pharma) which showed good correlation. 
In MTH immediate release layer, different concentration of 
superdisintegrants like SSG, CCS and PGS separately or in combination 
have shown different release pattern and different DT. With the use of 
mixture design 7 formulations were prepared in which M4 with 
combination of SSG and CCS showed minimum DT of 9 sec and maximum 
drug release of 98.31% in 15 min. Grid searches of above formulation 
gave 6 optimized formulations (F1-F6) in which formulation F6 
containing SSG (7.5%) and CCS (4.5%) showed 98.70% drug release in 15 
min. and DT of 8.86 sec. Concentration of SSG was found to be more 
significant than concentration of CCS in the optimized formulations of 
immediate release layer. Validated optimized formulation fulfilled all 
requisites of immediate release layer with good release rate and 
minimum DT.  
Above two optimized formulations as ACF conventional 
release layer and MTH immediate release layer were used to compare 
bilayer tablet which showed good correlation of release profile and also 
fulfills all evaluation parameters with long time stability. A stability study 
of physical mixture at 45 days and bilayer tablet was studied in which 
physical mixture was found to be degraded whereas bilayer tablet 
remains stable at 40ºC/75% RH as well as at ambient conditions. FT-IR 
study indicated loss of characteristic peak like N-H, C-H. C-Cl etc of MTH 
while N-H peak was found to absent for ACF in the physical mixture. In 
DSC study, broadening and shifting of characteristic melting point peak 
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was observed which indicate the degradation of physical mixture at 45 
days. Quantitative analysis of physical mixture as well as bilayer tablet at 
different time intervals showed the decrease in drug content of physical 
mixture while % drug content of bilayer tablet was within the range. 
Finally, Optimized immediate release layer of MTH and conventional 
release layer of ASF show satisfactory pre and post compression 
parameters. Bi-layer tablet of MTH and ASF might be suitable for 
treatment of migraine by sequential release of the drug. 
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